Abstracts tagged "Atherosclerosis"

Abstract Number: 644 • 2017 ACR/ARHP Annual Meeting
Association of Osteonectin, Osteopontin and Osteocalcin with Inflammation and Cardiovascular Risk in Patients with Axial Spondyloarthritis
Fernanda Genre¹, Javier Rueda-Gotor², Juan Irure-Ventura³, Sara Remuzgo-Martínez¹, Alfonso Corrales¹, Begoña Ubilla¹, Veronica Mijares¹, Carlos Fernández-Díaz¹, Virginia Portilla¹, Ricardo Blanco¹, Javier Llorca⁴, J. Gonzalo Ocejo-Vinyals³, Raquel López-Mejías¹ and Miguel Angel González-Gay⁵, ¹Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, IDIVAL, Santander, Spain, ²Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ³Immunology Division, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁴Department of Epidemiology and Computational Biology, School of Medicine, University of Cantabria, and CIBER Epidemiología y Salud Pública (CIBERESP), Santander, Spain, ⁵Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, IDIVAL and School of Medicine, University of Cantabria, Santander, Spain
Background/Purpose: A higher incidence of cardiovascular (CV) risk factors and atherosclerosis has been reported in axial spondyloarthritis (axSpA) patients1. Since axSpA (particularly AS) is an…
Abstract Number: 899 • 2017 ACR/ARHP Annual Meeting
Neutrophil Gene Signature and Low Density Granulocyte Subsets Associate with Coronary Plaque Burden and Vascular Inflammation in Systemic Lupus Erythematosus
Philip Carlucci¹, Monica Purmalek¹, Simantini Sakhardande¹, Yenealem Temesgen-Oyelakin¹, Amit K. Dey², Aditya A. Joshi², Joseph B. Lerman³, Alice Fike¹, Michael Davis⁴, Hong-Wei Sun¹, Jonathan H. Chung², Martin P. Playford², Pragnesh Mistry¹, Gustavo Gutierrez-Cruz¹, Stefania Dell'Orso¹, Faiza Naz¹, Heather Teague², Zerai G. Manna⁵, Peter C. Grayson¹, Mohammad Naqi¹, Marcus Chen², Sarfaraz A. Hasni¹, Nehal N. Mehta² and Mariana J. Kaplan¹, ¹NIH/NIAMS, Bethesda, MD, ²NIH/NHLBI, Bethesda, MD, ³NIH/CC, Bethesda, MD, ⁴NIH/NIAMS, Bethesda, IA, ⁵NIH/NIAMS, Bethesda, MD, Afghanistan
Background/Purpose: Systemic lupus erythematosus (SLE) increases a young woman’s risk of myocardial infarction by up to 50-fold. This marked increase in cardiovascular disease (CVD) risk…
Abstract Number: 964 • 2017 ACR/ARHP Annual Meeting
Atherogenic Potency of Plasma from Persons with Autoimmune Rheumatic Disorders: Comparative Effects on Cholesterol Flux in Human Macrophages
Andrew Maidhof¹, Allison B. Reiss^1,2, Lora J. Kasselman², Elise Belilos¹, Kristina Belostocki¹, Gary Rosenblum¹, Lois Bonnetti¹, Melissa Fazzari², Joshua DeLeon¹ and Steven E. Carsons^1,2, ¹NYU Winthrop University Hospital, Department of Medicine, Mineola, NY, ²NYU Winthrop University Hospital, Winthrop Research Institute, Mineola, NY
Background/Purpose: Although the risk of atherosclerotic cardiovascular disease and abnormalities in cholesterol transport have been demonstrated in rheumatoid arthritis (RA), lupus (SLE) and, to a…
Abstract Number: 87 • 2017 Pediatric Rheumatology Symposium
Assessment of Endothelial Dysfunction and Atherogenic Risk Factors in Children with Juvenile Dermatomyositis
Dawn Wahezi¹, Emily Liebling², Jillian Parekh², Marija Dionizovik-Dimanovski¹, Jaeun Choi³ and Qi Gao³, ¹Pediatric Rheumatology, Children's Hospital at Montefiore, Bronx, NY, ²Pediatrics, Children's Hospital at Montefiore, Bronx, NY, ³Albert Einstein College of Medicine, Bronx, NY
Background/Purpose: Endothelial pulse amplitude testing (Endo-PAT) measures changes in vascular tone by post-occlusive hyperemic response. A reduced hyperemic response suggests endothelial dysfunction and serves as…
Abstract Number: 1786 • 2016 ACR/ARHP Annual Meeting
Long-Term Evolution of Risk Factors for Atherosclerotic Cardiovascular Events in Systemic Lupus Erythematosus in a Large Case Control Cohort Study
Konstantinos Tselios¹, Dafna D Gladman², Jiandong Su³, Olga Ace⁴ and Murray Urowitz⁵, ¹Medicine, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²University of Toronto, Toronto, ON, Canada, ³Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ⁴University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁵Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Certain traditional and disease-related factors have been identified to accelerate atherosclerosis in systemic lupus erythematosus (SLE). Due to the lack of long-term prospective studies,…
Abstract Number: 1790 • 2016 ACR/ARHP Annual Meeting
Accrual of Disease Comorbidities over 8 Years in a Multicentre Inception SLE Cohort
Murray Urowitz¹, Dafna D Gladman², Nicole Anderson³, Jiandong Su⁴ and The Systemic Lupus International Collaborating Clinics (SLICC) Group, ¹Medicine, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ²University of Toronto, Toronto, ON, Canada, ³Division of Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ⁴Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada
Background/Purpose: The annual accrual of comorbidities in patients with SLE is not well described. We report the annual occurrence of these features in an inception…
Abstract Number: 738 • 2016 ACR/ARHP Annual Meeting
Preventive Effect of Combined Treatment with Bisphosphonate and Vitamin D on Atherosclerosis in Patients with Systemic Lupus Erythematosus
Kazumasa Ohmura, Masaru Kato, Toshiyuki Watanabe, Ryo Hisada, Masatoshi Kanda, Sanae Shimamura, Ikuma Nakagawa, Yuka Shimizu, Kenji Oku, Toshiyuki Bohgaki, Olga Amengual, Tetsuya Horita, Shinsuke Yasuda and Tatsuya Atsumi, Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Sapporo, Japan
Background/Purpose: Premature atherosclerosis is one of the major complications of systemic lupus erythematosus (SLE). Preventing atherosclerosis is a key objective while monitoring patients with SLE.…
Abstract Number: 2168 • 2016 ACR/ARHP Annual Meeting
Metabolic Syndrome, All Cause Mortality and Atherosclerotic Cardiovascular Disease in Rheumatic Diseases
Marco Antivalle^1,2, Valentina Varisco², Alessandra Mutti², Alberto Batticciotto², Maria Chiara Ditto², Fabiola Atzeni³ and Piercarlo Sarzi-Puttini², ¹Rheumatology, Rheumatology Unit, ASST Fatebenefratelli - Sacco, L. Sacco University Hospital, Milano, Italy, ²Rheumatology Unit, ASST Fatebenefratelli - Sacco, L. Sacco University Hospital, Milan, Italy, ³Rheumatology Unit, ASST Fatebenefratelli - Sacco, L. Sacco University Hospital, Milano, Italy
Background/Purpose: all-cause and cardiovascular mortality and cardiovascular morbidity are reportedly increased in rheumatic diseases, both inflammatory and non-inflammatory. Few studies, however have addressed the impact…
Abstract Number: 880 • 2016 ACR/ARHP Annual Meeting
Pilot Study of Microbubble Contrast-Enhanced Vascular Ultrasonography: A Novel Method of Detecting Large Vessel Vasculitis?
Kimberly P. Liang¹, Douglas P. Landsittel², Bernadette B. Sendon³, Donald M. Jones⁴, Suresh R. Mulukutla⁵, Steven E. Reis⁶, Ali Hakim Shoushtari⁷ and Larry W. Moreland⁸, ¹Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ²Medicine, University of Pittsburgh, Pittsburgh, PA, ³Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁴Rheumatology & Clinical Immunology, Univ of Pittsburgh Med Ctr, Pittsburgh, PA, ⁵Division of Cardiology, University of Pittsburgh, Pittsburgh, PA, ⁶Division of Cardiology and Department of Clinical and Translational Science, University of Pittsburgh, Pittsburgh, PA, ⁷Clinical and Translational Science Institute, University of Pittsburgh, Pittsburgh, PA, ⁸Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: A key unmet need in the monitoring of disease activity in large vessel vasculitides (LVV), i.e., giant cell arteritis (GCA) and Takayasu arteritis…
Abstract Number: 2425 • 2016 ACR/ARHP Annual Meeting
The Vasculopathy of Juvenile Dermatomyositis (JDM); Evidence of Persistent Endothelial Injury, Hypercoagulability, Subclinical Inflammation and Increased Arterial Stiffness
Charalampia Papadopoulou^1,2, Ying Hong¹, Petra Krol^1,2, Yiannis Ioannou³, Clarissa Pilkington^2,4,5, Hema Chaplin⁶, Stephanie Simou¹, Marietta Charakida⁷, Lucy R Wedderburn^5,8,9, Paul Brogan¹⁰ and Despina Eleftheriou^1,8,11, ¹Infection, Inflammation and Rheumatology, UCL Institute of Child Health, London, United Kingdom, ²Paediatric Rheumatology, Great Ormond Street Hospital NHS Trust, London, United Kingdom, ³Rayne Institute, Arthritis Research UK Centre for Adolescent Rheumatology, UCL Division of Medicine, London, United Kingdom, ⁴Paediatric Rheumatology, Great Ormond Street Hospital for Children NHS Trust, London, United Kingdom, ⁵Infection, Inflammation and Rheumatology Section, UCL Institute of Child Health, London, United Kingdom, ⁶Centre for Adolescent Rheumatology, Arthritis Research UK, London, United Kingdom, ⁷Vascular Physiology Unit, Institute of Cardiovascular Science , University College London, London, United Kingdom, ⁸Paediatric Rheumatology Department, Great Ormond Street Hospital for Children NHS Trust, London, United Kingdom, ⁹Rheumatology Unit, Arthritis Research UK Centre for Adolescent Rheumatology, University College London, London, United Kingdom, ¹⁰Department of Paediatric Rheumatology, UCL Institute of Child Health and Great Ormond Street Hospital NHS Foundation Trust, London, United Kingdom, ¹¹Arthritis Research UK Centre for Adolescent Rheumatology, University College London, London, United Kingdom
Background/Purpose: Vasculopathy is considered central to the pathogenesis of Juvenile Dermatomyositis (JDM). The interplay between persistent JDM-vasculopathy, traditional cardiovascular risk factors, exposure to corticosteroids, and…
Abstract Number: 1178 • 2016 ACR/ARHP Annual Meeting
Is Subclinical Atherosclerosis Prevalent in a French Patient Cohort with Systemic Lupus Erythematosus?
Tess Van Meerhaeghe¹, Alexis Mathian¹, Matthieu Wargny¹, Miguel HIe¹, Micheline Pha¹, Julien Haroche², Fleur Cohen¹, Thi-Huang Du Boutin¹ and Zahir Amoura¹, ¹Department of Internal Medicine 2. Referal center for SLE/APS, Hôpital Pitié-Salpêtrière, AP-HP, UPMC Univ Paris 06 & French National Reference Center For Systemic Lupus and Antiphospholipid Syndrome, Paris, France, ²Internal Medicine 2. Referal center for SLE/APS, Hôpital Pitié-Salpêtrière, AP-HP, UPMC Univ Paris 06 & French National Reference Center For Systemic Lupus and Antiphospholipid Syndrome, Paris, France
Background/Purpose: Systemic lupus erythematosus (SLE) seems associated with an increased risk of cardiovascular disease. These data are mainly based on studies mostly from North America.…
Abstract Number: 2463 • 2016 ACR/ARHP Annual Meeting
Association Between High Sodium Intake and Subclinical Atherosclerosis in Patients with Rheumatoid Arthritis
Gulsen Ozen¹, Ali Ugur Unal², Simge Saydam³, Murat Sunbul⁴, Kursat Tigen⁴, Haner Direskeneli⁵ and Nevsun Inanc¹, ¹Department of Rheumatology, Marmara University Faculty of Medicine, Istanbul, Turkey, ²Marmara University, School of Medicine, Rheumatology, Istanbul, Turkey, ³Marmara University Faculty of Medicine, Istanbul, Turkey, ⁴Department of Cardiology, Marmara University Faculty of Medicine, Istanbul, Turkey, ⁵Rheumatology, Marmara University, School of Medicine, Istanbul, Turkey
Background/Purpose: High sodium intake has been reported to be associated with increased ACPA positivity in smoker RA patients. However, apart from this, the associations with…
Abstract Number: 1465 • 2016 ACR/ARHP Annual Meeting
Utility of Relative Cardiovascular Risk Score Scales in Patients UNDER the Age of 50 and Its Association with the Presence of Carotid Atherosclerosis in the Ultrasound
Andrea Zacarias¹, Carmen Gomez Vaquero², Francisco Javier Narváez³, Miguel Angel González-Gay⁴, Alfonso Corrales⁵, Carlos González-Juanatey⁶, Javier Llorca⁷ and Joan Miquel Nolla⁸, ¹Hospital Universitari de Bellvitge, Barcelona, Spain, ²Department of Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, ³Rheumatology, Hospital Universitario de Bellvitge-IDIBELL, L’Hospitalet de Llobregat, Barcelona, Spain, ⁴Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, University of Cantabria, Santander, Spain, ⁵Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain, ⁶Cardiology Division, Hospital Xeral-Calde, Lugo, Spain, ⁷Department of Epidemiology and Computational Biology, School of Medicine, University of Cantabria, and CIBER Epidemiología y Salud Pública (CIBERESP), IDIVAL, Santander, Spain, ⁸Rheumatology, Bellvitge University Hospital, Barcelona, Spain
Background/Purpose: Rheumatoid Arthritis (RA) is associated with a greater cardiovascular mortality than the general population of the same age and gender. Cardiovascular events prediction scales,…
Abstract Number: 2781 • 2016 ACR/ARHP Annual Meeting
Immunization with ApoB100 Peptide Vaccine Reduces Atherosclerosis Development in a Mouse Model of Systemic Lupus Erythematosus
Ingrid Yao-Mattisson, Maria Wigren, Gunilla Nordin Fredrikson and Jan Nilsson, Lund University, Malmö, Sweden
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by impaired self-tolerance causing damage to multiple organs including the cardiovascular system. Current therapies do…
Abstract Number: 1466 • 2016 ACR/ARHP Annual Meeting
Cardiovascular Risk Assessment in Persons with Rheumatoid Arthritis: A Correlative Study of Non-Invasive Arterial Health Testing with the Inflammatory Burden of Disease
Erin Scanlon¹, Rekha Mankad², Cynthia S. Crowson³, Iftikhar Kullo⁴, Sharon Mulvagh², Eric L. Matteson¹, Zoran Kvrgic¹ and John M. Davis III⁵, ¹Rheumatology, Mayo Clinic, Rochester, MN, ²Cardiovascular Diseases, Mayo Clinic, Rochester, MN, ³Health Sciences Research, Mayo Clinic, Rochester, MN, ⁴Department of Internal Medicine, Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN, ⁵Division of Rheumatology, Mayo Clinic, Rochester, MN
Background/Purpose: Persons with rheumatoid arthritis (RA) have increased morbidity and mortality attributable to atherosclerotic cardiovascular disease (ASCVD) events. It is unknown how presence of subclinical…

« Previous Page
1
…
6
7
8
9
10
…
17
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].